Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Single Dose Study of SKY-GJB2 Given as a Single Unilateral Intracochlear Administration in Pediatric Subjects With GJB2-mediated Hearing Loss

NCT07627971 is registered in ClinicalTrials.gov with Skylark Bio Inc. as lead sponsor.

NCT NCT07627971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07627971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Single Dose Study of SKY-GJB2 Given as a Single Unilateral Intracochlear Administration in Pediatric Subjects With GJB2-mediated Hearing Loss
Lead sponsor
Skylark Bio Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 28, 2026
Completion date
June 30, 2028
Enrollment
10 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dfnb1a, gjb2 gene mutation, gjb2-mediated hearing loss